Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 13/20 | 0.72 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.39 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.39 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2201950 | 1.00 | METAP2 (0.72) | METAP2FFAR2CHRNB4CHRNA3CHRNB2 | |
| SCHEMBL2201957 | 1.00 | METAP2 (0.72) | METAP2FFAR2CHRNB4CHRNA3CHRNB2 | |
| SCHEMBL2199826 | 0.90 | METAP2 (0.58) | METAP2FFAR2CHRNB4CHRNA3ADORA3 | |
| SCHEMBL2199840 | 0.90 | METAP2 (0.58) | METAP2FFAR2CHRNB4CHRNA3ADORA3 | |
| SCHEMBL2198194 | 0.88 | METAP2 (0.56) | METAP2FFAR2CHRNB4CHRNA3ADORA3 | |
| SCHEMBL2202736 | 0.88 | METAP2 (0.56) | METAP2FFAR2CHRNB4CHRNA3ADORA3 | |
| SCHEMBL2198189 | 0.88 | METAP2 (0.61) | METAP2FFAR2ADORA3ADORA2AADORA1 | |
| SCHEMBL2201270 | 0.88 | METAP2 (0.56) | METAP2FFAR2CHRNB4CHRNA3ADORA3 | |
| SCHEMBL2198182 | 0.88 | METAP2 (0.61) | METAP2FFAR2ADORA3ADORA2AADORA1 | |
| SCHEMBL2203237 | 0.88 | METAP2 (0.72) | METAP2FFAR2CHRNB4CHRNA3ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1912994-B1 | ADENINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-03-12 | — | — | EP | claimed |
| US-20100160352-A1 | ADENINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2010-06-24 | — | — | US | claimed |
| EP-1912994-B1 | ADENINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160352-A1 | ADENINE DERIVATIVES | HSP90AA1, TRAP1, HSP90AB1 | METAP2 3595/4885FFAR2 4622/4885CHRNB4 4645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.